<?xml version="1.0" encoding="UTF-8"?><own:edgarSubmission xmlns:com="http://www.sec.gov/edgar/common" xmlns:own="http://www.sec.gov/edgar/ownership">
  <!-- Generated by Workiva -->
  <own:headerData>
    <own:submissionType>144/A</own:submissionType>
    <own:previousAccessionNumber>0001968582-26-000868</own:previousAccessionNumber>
    <own:filerInfo>
      <own:filer>
        <own:filerCredentials>
          <own:cik>0002000389</own:cik>
          <own:ccc>XXXXXXXX</own:ccc>
        </own:filerCredentials>
      </own:filer>
      <own:liveTestFlag>LIVE</own:liveTestFlag>



    </own:filerInfo>
  </own:headerData>
  <own:formData>
    <own:issuerInfo>
      <own:issuerCik>0001936258</own:issuerCik>
      <own:issuerName>NewAmsterdam Pharma Company N.V.</own:issuerName>
      <own:secFileNumber>001-41562</own:secFileNumber>
      <own:issuerAddress>
        <com:street1>Gooimeer 2-35</com:street1>
        <com:city>DC Naarden</com:city>
        <com:stateOrCountry>P7</com:stateOrCountry>
        <com:zipCode>1411</com:zipCode>
      </own:issuerAddress>
      <own:issuerContactPhone>31-0-35-206-2971</own:issuerContactPhone>
      <own:nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Kastelein Johannes Jacob Pieter</own:nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <own:relationshipsToIssuer>
        <own:relationshipToIssuer>Affiliate</own:relationshipToIssuer>
      </own:relationshipsToIssuer>
    </own:issuerInfo>
    <own:securitiesInformation>
      <own:securitiesClassTitle>Ordinary Shares</own:securitiesClassTitle>
      <own:brokerOrMarketmakerDetails>
        <own:name>J.P. Morgan Securities LLC</own:name>
        <own:address>
          <com:street1>270 Park Avenue - 10th Floor</com:street1>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10017</com:zipCode>
        </own:address>
      </own:brokerOrMarketmakerDetails>
      <own:noOfUnitsSold>250000</own:noOfUnitsSold>
      <own:aggregateMarketValue>6967500</own:aggregateMarketValue>
      <own:noOfUnitsOutstanding>119537169</own:noOfUnitsOutstanding>
      <own:approxSaleDate>08/25/2026</own:approxSaleDate>
      <own:securitiesExchangeName>Nasdaq</own:securitiesExchangeName>
    </own:securitiesInformation>
    <own:securitiesToBeSold>
      <own:securitiesClassTitle>Ordinary Shares</own:securitiesClassTitle>
      <own:acquiredDate>08/24/2026</own:acquiredDate>
      <own:natureOfAcquisitionTransaction>Option Exercise</own:natureOfAcquisitionTransaction>
      <own:nameOfPersonfromWhomAcquired>Issuer</own:nameOfPersonfromWhomAcquired>
      <own:isGiftTransaction>N</own:isGiftTransaction>
      <own:amountOfSecuritiesAcquired>250000</own:amountOfSecuritiesAcquired>
      <own:paymentDate>08/24/2026</own:paymentDate>
      <own:natureOfPayment>Cash</own:natureOfPayment>
    </own:securitiesToBeSold>
    <own:nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</own:nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <own:remarks>The shares represented on this filing are for shares expected to be sold in the next 90 days by Futurum B.V., John Kastelein as Director</own:remarks>
    <own:noticeSignature>
      <own:noticeDate>08/24/2026</own:noticeDate>
      <own:planAdoptionDates>
        <own:planAdoptionDate>03/31/2026</own:planAdoptionDate>
      </own:planAdoptionDates>
      <own:signature>/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Kastelein Johannes Jacob Pieter</own:signature>
    </own:noticeSignature>
  </own:formData>
</own:edgarSubmission>
